122 results about "Nasopharyngeal Cancers" patented technology

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.

The present invention discloses two antigen protein fragments of protein product Rta of nasopharyngeal specific gene BRLF1, encoding gene, recombinant carrier, fusion protein (GST and GST-R185-R150), nasopharyngeal cancer diagnosis agent containing the compounds and the ELISA agent box, as well as the application of the compounds in detection of EB virus in vitro. The ELISA agent box of the present invention can be used for nasopharyngeal cancer screening, early diagnosis and forecasts of treatment results. The present invention has the advantages of simplicity, sensitivity and specificity, and is suitable for early diagnosis and forecasts of nasopharyngeal carcinoma, and the large-scale screening of high-risk groups. The present invention is easy to be widely promoted and used; the use is safe and clean; the present invention has broad market prospects.

The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and / or human breast cancer cell.

The invention discloses a preparation method for a replication and transcription activator (Rta) protein and the application of the Rta protein to a nasopharynx cancer detection reagent and relates to a medical diagnosis reagent. The preparation method disclosed by the invention comprises the following steps of: 1, constructing a recombinant expression vector by taking a BRLF1 full-length gene as an exogenous gene; 2, transfecting: transfecting the recombinant expression vector into an eukaryotic expression system to obtain a positive transfected cell; and 3, expressing and purifying: culturing the positive transfected cell so as to enable the positive transfected cell to express an interest protein, and separating and purifying the interest protein, wherein the eukaryotic expression system refers to a Chinese hamster ovary (CHO) cell. The Rta protein prepared by the method disclosed by the invention is used for detecting nasopharynx cancer; the sensitivity of the Rta protein is 96 percent (288 / 300), and the specificity of the Rta protein is 96.7 percent (290 / 300). The sensitivity and the specificity are superior to those of antigens respectively prepared by a prokaryotic expression system and a pichia expression system, and the sensitivity and the specificity on clinical early diagnosis on the nasopharynx cancer are greatly improved.

The invention discloses an application of a compound as a JAK-STAT3 signal passage inhibitor, and particularly relates to an application of a compound with a formula I or pharmaceutically acceptable salt of the compound in the process of preparing an anti-tumor medicament. The application provides a novel treating candidate medicament for a tumor patient, thereby probably further improving the treatment effect on the patient and improving the prognosis of the patient. The compound with the formula I or the pharmaceutically acceptable salt of the compound has the effect on various tumor cells, which indicates that the compound can be used for treating various cancers including cerebral tumor, genitourinary system tumor, lymphatic system tumor, stomach cancer, laryngeal cancer, nasopharyngeal cancer, skin cancer, bone cancer, blood cancer, leukemia, breast cancer and histiocytic lymphoma, non-small cell lung cancer, small-cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, pancreatic cancer, prostatic cancer, liver cancer, epithelial cell cancer and the like. The definition of genes in the formula refers to description for details.

The invention relates to an application of a macrolide compound in reversing tumor multidrug resistance and enhancing an anti-tumor curative effect. The compound has the functions of inhibiting ABC transport protein activity, improving the concentration of a substrate chemotherapeutic drug of the ABC transport protein in tumor cells, reversing tumor multidrug resistance, and enhancing curative effects of the ABC transport protein substrate chemotherapeutic drugs such as antibiotic tumor chemotherapeutic drugs, plant-derived tumor chemotherapeutic drugs and small-molecular tyrosine kinase inhibitors, and has an effect of enhancing curative effects when being combined with antitumor drugs. Effective dose of the compound is combined with effective dose of an anti-tumor drug for application, apharmaceutically acceptable compound preparation is prepared by mixing with an effective dose of the antitumor drug, and is used for treating tumors including leukemia, lymphoma, gastric cancer, colon cancer, liver cancer, pancreatic cancer, breast cancer, nasopharyngeal carcinoma, cervical carcinoma, melanoma, multiple myeloma, and sarcoma.

The invention relates to the field of image processing, and provides a method and device for automatically identifying nasopharyngeal carcinoma primary tumors. The method comprises the steps: employing a ResNeXt152 network as a backbone network in a Mask RCNN deep semantic segmentation network, and defining the prediction types of semantic segmentation branches into three types; training the deepsemantic segmentation network by utilizing a plurality of preprocessed magnetic resonance three-dimensional images, and outputting pixel position information of four end points of a rectangular framecontaining a tumor region, the probability that the rectangular frame is the tumor region and the probability that each pixel in the rectangular frame belongs to a primary tumor region; and inputtinga to-be-recognized magnetic resonance three-dimensional image into the deep semantic segmentation network to obtain the probability that each pixel belongs to a primary tumor region. According to themethod, through a deep learning method, a Mask RCNN network architecture is utilized and improved, so that the prediction accuracy and the generalization ability of the model can be effectively improved.

The invention belongs to the field of chemical pharmaceuticals, and more specifically relates to 7-oxy, thio or imino substituted coumarin with a structure represented by formula 8 or 12, and derivatives and antineoplastic activity thereof. The results of antineoplastic activity and pharmacological target experiments show that 7-oxy, thio or imino substituted coumarin derivatives possess inhibitory activity on the growth of nasopharyngeal carcinoma cells and drug-resistant tumor strains of nasopharyngeal carcinoma cells, lung cancer cells and prostatic cancer cells; and the results of pharmacological research show that 7-oxy, thio or imino substituted coumarin is capable of promoting cell apoptosis and influencing cell division cycle G2 / M. 7-oxygen, sulfur or nitrogen substituted coumarin is novel in structure, and is capable of providing basis for intensive study on target sports and related pharmacological mechanisms such as reversing drug-resistance mechanism. X is selected from oxygen, sulfur or nitrogen atoms; R2 is selected from alkyl, alkoxy, halogenated alkyl groups or ester group; and R3 is selected from alkyl, and substituted aromatic heterocyclic compounds including 6-chloropyridine and substituted aralkyl.

The invention relates to ozonization oil for cancer prevention and treatment and a combination drug with an anti-cancer drug. Particularly, the ozonization oil is used for preventing and treating liver cancer, lung cancer, stomach cancer, colorectal cancer, rectal cancer, esophagus cancer, breast cancer, cervical cancer, prostatic cancer, skin cancer and nasopharyngeal cancer by means of oral administration.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Hepatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and / or adefovir resistant) and other mutant forms of these viruses, especially HBV.

An oncolytic virus is for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patientswith no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / orcancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panelof three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

The invention relates to preparation and application of a novel organo-antimony complex (1). The complex (1) has the characteristics of high anticancer activity, large water solubility, small toxic side effect and the like. A drug effect composition containing the complex (1) is used for treating various solid cancers, such as lung cancer, gastric carcinoma, liver cancer, breast carcinoma, cancer of colon, ovarian cancer, cervical carcinoma, leukemia, lymphoma, nasopharyngeal darcinoma and the like.

The invention discloses an application of baicalein to the preparation of a drug for preventing and / or treating nasopharyngeal carcinoma. The application firstly proves that baicalein can remarkably inhibit a viral protein EBNA1 on which an Epstein-Barr virus exists, and a cell can become a normal cell due to tumor virus loss caused by overlow existing quantity of the protein in the cell. Baicalein can be favorably used for treating precancerous lesion, the conversion of severe rhinitis to nasopharyngeal carcinoma is effectively stopped, and the application has important significance for treating the precancerous lesion of nasopharyngeal carcinoma and reducing the occurrence rate and fatality rate of nasopharyngeal carcinoma.

The invention belongs to the technical field of affinal-drug-and-diet formulas and new-resource foods, and particularly provides a medical formula food, a special medical formula food or a non-special medical formula food for nasopharynx cancer patients. The formula is designed according to the requirement in "National Food Safety Standard General Rules on Formula Food for Special Medical Use". With consideration of the body characters of the nasopharynx cancer patients, various "affinal-drug-and-diet" traditional Chinese medicines are combined reasonably according to traditional Chinese medicine essential principles, and a plurality of affinal-drug-and-diet traditional Chinese medicine extract essences which are extracted through a pre-hydrolysis SBE technology, various micro-capsulated probiotics, oligopeptides extracted through bio-enzymolysis, prebiotics, amino acids, carbohydrates, grease having health-caring functions, various vitamins and minerals are all mixed together and are subjected to other processes to obtain the medical formula food. The medical formula food can be used for satisfying nutrition requirement of the nasopharynx cancer patients as a single nutritional source, and has the functions of nourishing yin and clearing heat, boosting qi and soothing throat, tonifying and boosting qi and blood, harmonizing ying and removing toxin, softening hardness and dissipating binds, and enhancing body immunity.